INMB Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -78750% compared to INmune Bio's net margin of -49.65%. INmune Bio's return on equity of -79.18% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

INmune Bio has a consensus price target of $19.67, signalling upside risk potential of 274.57%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than INmune Bio, analysts believe NovaBay Pharmaceuticals is more attractive than INmune Bio.

INmune Bio has a beta of 1.782, which suggesting that the stock is 78.164% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

INmune Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

INmune Bio quarterly revenues are $14K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. INmune Bio's net income of -$12.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, INmune Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio is 763.35x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -78750% compared to INmune Bio's net margin of --. INmune Bio's return on equity of -79.18% beat Oragenics's return on equity of --.

INmune Bio has a consensus price target of $19.67, signalling upside risk potential of 274.57%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 26002.08%. Given that Oragenics has higher upside potential than INmune Bio, analysts believe Oragenics is more attractive than INmune Bio.

INmune Bio has a beta of 1.782, which suggesting that the stock is 78.164% more volatile than S&P 500. In comparison Oragenics has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.712%.

INmune Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

INmune Bio quarterly revenues are $14K, which are larger than Oragenics quarterly revenues of --. INmune Bio's net income of -$12.1M is lower than Oragenics's net income of -$2.5M. Notably, INmune Bio's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio is 763.35x versus 1.36x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -78750% compared to INmune Bio's net margin of -2357.27%. INmune Bio's return on equity of -79.18% beat Palatin Technologies's return on equity of --.

INmune Bio has a consensus price target of $19.67, signalling upside risk potential of 274.57%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than INmune Bio, analysts believe Palatin Technologies is more attractive than INmune Bio.

INmune Bio has a beta of 1.782, which suggesting that the stock is 78.164% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

INmune Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

INmune Bio quarterly revenues are $14K, which are smaller than Palatin Technologies quarterly revenues of $350K. INmune Bio's net income of -$12.1M is lower than Palatin Technologies's net income of -$7.8M. Notably, INmune Bio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio is 763.35x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -78750% compared to INmune Bio's net margin of --. INmune Bio's return on equity of -79.18% beat Theriva Biologics's return on equity of --.

INmune Bio has a consensus price target of $19.67, signalling upside risk potential of 274.57%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5591.82%. Given that Theriva Biologics has higher upside potential than INmune Bio, analysts believe Theriva Biologics is more attractive than INmune Bio.

INmune Bio has a beta of 1.782, which suggesting that the stock is 78.164% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

INmune Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

INmune Bio quarterly revenues are $14K, which are larger than Theriva Biologics quarterly revenues of --. INmune Bio's net income of -$12.1M is lower than Theriva Biologics's net income of -$7.7M. Notably, INmune Bio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio is 763.35x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.